Tramadol induced paradoxical hyperalgesia

Pain Physician

Volumn 16, Issue 1, 2013, Pages 41-44

  Lee, Seong Heon ^a   Cho, Soo Young ^a   Lee, Hyung Gon ^a   Choi, Jeong Il ^a   Yoon, Myung Ha ^a   Kim, Woong Mo ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Chronic pain; Ketamine; Opioid induced hyperalgesia; Opioids; Serotonin syndrome; Tramadol

Indexed keywords

FENTANYL; KETAMINE; MIDAZOLAM; MU OPIATE RECEPTOR; OXYCODONE; PARACETAMOL; PREGABALIN; TIANEPTINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; BURNING SENSATION; CHILL; CHRONIC PAIN; CLINICAL ARTICLE; DERMATOME; DIAPHORESIS; DISEASE EXACERBATION; DRUG DOSE INCREASE; FEMALE; HUMAN; HYPERALGESIA; IRRITABILITY; MAINTENANCE DRUG DOSE; MALE; MYOCLONUS; POSTHERPETIC NEURALGIA; RHINORRHEA; TREMOR;

AGED; ANALGESICS, OPIOID; CHRONIC PAIN; FEMALE; HUMANS; HYPERALGESIA; MALE; MIDDLE AGED; TRAMADOL;

EID: 84872810314     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Silverman SM. Opioid induced hyperalgesia: Clinical implications for the pain practitioner. Pain Physician 2009; 12:679-684.
2. Angst MS, Clark JD. Opioid-induced hyperalgesia: A qualitative systematic review. Anesthesiology 2006; 104:570-587.
3. Porreca F. Opiates - Pharmacology of Pain. In: Schmidt RF, Willis WD (ed) Encyclopedia of Pain. 1st ed. Springer, New York, 2007, pp 2504-2505.
4. Sansone RA, Sansone LA. Tramadol: Seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry (Edgmont) 2009; 6:17-21.
5. Manchikanti L, Ailinani H, Koyyalagunta Datta S, Singh V, Eriator I, Sehgal N, Shah R, Benyamin R, Vallejo R, Fellows B, Christo PJ. A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. Pain Physician 2011; 14:91-121.
6. Manchikanti L, Vallejo R, Manchikanti KN, Benyamin RM, Datta S, Christo PJ. Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician 2011; 14:E133-E156.
7. Knisely JS, Campbell ED, Dawson KS, Schnoll SH. Tramadol post-marketing surveillance in health care professionals. Drug Alcohol Depend 2002; 68:15-22.
8. Govind J. Tramadol hydrochloride. In: Schmidt RF, Willis WD (eds). Encyclopedia of Pain. 1st ed. Springer, New York, 2007, pp 2504-2505.
9. Hennies HH, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittel-Forschung 1988; 38:877-880.
10. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992; 260:275-85.
11. Spiller HA, Gorman SE, Villalobos D, Benson BE, Ruskosky DR, Stancavage MM, Anderson DL. Prospective multicenter evaluation of tramadol exposure. J Toxicol Clin Toxicol 1997; 35:361-364.
12. Ide S, Minami M, Ishihara K, Uhl GR, Sora I, Ikeda K. Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology 2006; 51:651-658.
13. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain 1995; 62:259-274.
14. Dvir Y, Smallwood P. Serotonin syndrome: A complex but easily avoidable condition. Gen Hosp Psychiatry 2008; 30:284-287.
15. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. Qjm 2003; 96:635-642.
16. Brush DE. Complications of long-term opioid therapy for management of chronic pain: The paradox of opioid-induced hyperalgesia. J Med Toxicol 2012; 8:387-392.
17. Xie JY, Herman DS, Stiller CO, Gardell LR, Ossipov MH, Lai J, Porreca F, Vanderah TW. Cholecystokinin in the rostral ventromedial medulla mediates opioidinduced hyperalgesia and antinociceptive tolerance. J Neurosci 2005; 25:409-416.
18. Arcaya JL, Cano G, Gomez G, Maixner W, Suarez-Roca H. Dynorphin A increases substance P release from trigeminal primary afferent C-fibers. Eur J Pharmacol 1999; 366:27-34.
19. Gardell LR, Wang R, Burgess SE, Ossipov MH, Vanderah TW, Malan TP Jr, Lai J, Porreca F. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002; 22:6747-6755.
20. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994; 14:2301-2312.
21. Mercadante S, Villari P, Ferrera P. Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symtom Manage 2003; 25:302-305.
22. Hong BH, Lee WY, Kim YH, Yoon SH, Lee WH. Effects of intraoperative low dose ketamine on remifentanil-induced hyperalgesia in gynecologic surgery with sevoflurane anesthesia. Korean J Anesthesiol 2011; 61:238-243.
23. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997; 278:58-63.
24. Punch LJ, Self DW, Nestler EJ, Taylor JR. Opposite modulation of opiate withdrawal behaviors on microinfusion of a protein kinase A inhibitor versus activator into the locus coeruleus or periaqueductal gray. J Neurosci 1997; 17:8520-8527.
25. Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: Biochemical and pharmacological evidence. Neurosci Biobehav Rev 1997; 21:91-104.
26. Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schuttler J. Differential modulation of remifentanilinduced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology 2003; 99:152-159.